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Background
Approaches that target key HPV genes critical for can-
cer growth and metastasis may improve survival for
individuals diagnosed with carcinomas of the uterine
cervix or head and neck. ADXS11-001 is a live attenu-
ated Listeria monocytogenes (Lm)-listeriolysin O (LLO)
immunotherapy bioengineered to secrete an HPV-E7
tumor antigen as a truncated LLO-E7 fusion protein in
cells capable of presenting antigen. This results in HPV-
specific T-cell generation, reducing tumor protection in
the tumor microenvironment. MEDI4736, an anti-
programmed death-1 ligand (PD-L1) antibody, blocks
the binding of PD-L1 to PD-1 and CD8, and relieves the
inhibition of PD-L1–dependent immunosuppressive
effects. Inhibition of PD-L1 binding increased the appar-
ent immunologic potency/activity of ADXS11-001 in a
preclinical study that showed the combination of
ADXS11-011 and an anti–PD-L1 significantly retards
tumor growth and prolongs survival in animals.
Methods
This is an open-label, multicenter, 2-part, randomized
Phase I/II study (NCT02291055). Patients (≥18 years)
with squamous/nonsquamous cervical carcinoma or
HPV-associated squamous cell cancer of the head and
neck who progressed on ≥1 prior platinum-based ther-
apy in the recurrent/metastatic setting are eligible. The
primary objective of Phase I is to evaluate the safety and
tolerability of ADXS11-001 plus MEDI4736 and select a
recommended Phase II dose (RP2D) for the combina-
tion. The primary objective of Phase II is to evaluate the
tumor response, progression-free survival (PFS), and
safety of ADXS11-001 and MEDI4736 as monotherapy
and in combination. Exploratory objectives for both
phases will evaluate associations between biomarkers of
immunologic response with tumor response and PFS. In
Phase I, up to 18 patients will receive a fixed dose of
ADXS11-001 (1×109 colony-forming units [CFU]), while
the dose of MEDI4736 will be escalated (starting at
3 mg/kg) according to a standard 3+3 design. In Phase II,
patients (n≈48) will be randomized (1:1:2) to receive either
ADXS11-001 (1×109 CFU) or MEDI4736 (10 mg/kg) or
both at the RP2D; all treatment arms will be stratified by
disease. In both phases, ADXS11-001 will be administered
every 4 weeks and MEDI4736 every 2 weeks. Patients will
receive treatment up to 1 year or until they discontinue
due to disease progression or unacceptable toxicity.
Efficacy parameters will be evaluated by Response
Evaluation Criteria in Solid Tumors (RECIST) and
immune-related RECIST criteria, and safety determined
using the Common Terminology Criteria for Adverse
Events (CTCAE). Enrollment for this study is anticipated
in July 2015.
Trial registration
ClinicalTrials.gov identifier NCT02291055.1University of California, San Diego Moores Cancer Center, La Jolla, CA, USA
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